Loading clinical trials...
Loading clinical trials...
A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-based Chemotherapy
The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.
Age
18 - 130 years
Sex
FEMALE
Healthy Volunteers
No
Research Site
Los Angeles, California, United States
Research Site
San Francisco, California, United States
Research Site
Boca Raton, Florida, United States
Research Site
Boston, Massachusetts, United States
Research Site
New York, New York, United States
Research Site
Houston, Texas, United States
Research Site
East Melbourne, Australia
Research Site
Melbourne, Parkville, Australia
Research Site
Randwick, Australia
Research Site
Leuven, Belgium
Start Date
July 30, 2008
Primary Completion Date
September 15, 2009
Completion Date
September 19, 2018
Last Updated
December 5, 2019
97
ACTUAL participants
AZD2281
DRUG
Liposomal Doxorubicin
DRUG
AZD2281
DRUG
Lead Sponsor
AstraZeneca
NCT07213804
NCT06051695
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions